Signaling Pathway
Product type
Important Notice: For research use only. We do not sell to patients.
Loading distributor info...
| Discription | BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1. | ||
|---|---|---|---|
| Targets |
|
| Catalog Num | A15762 |
|---|---|
| Formula | C29H28N4O2 |
| Molecular Weight | 464.56 |
| CAS Number | 1207293-36-4 |
| SMILES | CCNC(C#CC1=CC=C2C(NC(/C2=C(NC3=CC=C(CN(C)C)C=C3)/C4=CC=CC=C4)=O)=C1)=O |
| Synonyms | BI 847325, BI847325 |
| Storage | Store lyophilized at -20ºC, keep desiccated. |
| In vitro (25°C) | DMSO | Warmed: 19 mg/mL (40.89 mM) | |
| Water | Insoluble | ||
| Ethanol | 1 mg/mL (2.15 mM) | ||
| In vivo | 2-hydroxyethyl cellulose, polysorbate 80 with pH adjusted to 2.8 with 1 M HCl | 28 mg/mL | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 21.53 mL | 107.63 mL | 215.26 mL |
| 0.5 mM | 4.31 mL | 21.53 mL | 43.05 mL |
| 1 mM | 2.15 mL | 10.76 mL | 21.53 mL |
| 5 mM | 0.43 mL | 2.15 mL | 4.31 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
